Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1

Conditions

Breast Neoplasms 9Endometrial Neoplasms 4Carcinoma, Renal Cell 4Neuroendocrine Tumors 3Tuberous Sclerosis 2Recurrence 2Neoplasm Metastasis 2Kidney Neoplasms 2Thyroid cancer, Hurthle cell 1Thyroid Neoplasms 1Thyroid Diseases 1Solid Tumor 1Seizures 1Sarcoma 1Primary Non-metastatic Breast Cancer 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Multiple Endocrine Neoplasia Type 1 1Liposarcoma 1Leukemia, Myeloid, Acute 1Leiomyosarcoma 1Gastro-enteropancreatic neuroendocrine tumor 1Endometrial Hyperplasia 1Clear-cell metastatic renal cell carcinoma 1Breast Neoplasms, Male 1Angiomyolipoma 1Advanced Solid Tumors 1Advanced Cancer 1

Interventions

fludarabine 19Cyclophosphamide 19fludarabine phosphate 16Azacitidine 14Tacrolimus 13Melphalan 13venetoclax 10Cytarabine 10Busulfan 10Whole-Body Irradiation 9Thiotepa 9Mycophenolic Acid 9Stem Cell Transplantation 7Peripheral Blood Stem Cell Transplantation 7Decitabine 7decitabine and cedazuridine drug combination 6Methotrexate 6Granulocyte Colony-Stimulating Factor 6Specimen Handling 5Sirolimus 5CPX-351 5AP 1903 reagent 5thymoglobulin 4Vorinostat 4Mesna 4Injections 4Daunorubicin 4Biopsy 4Ipilimumab 3Filgrastim 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × Myelodysplastic Syndromes × Everolimus × Clear all
NCT00819546 2026-03-25

RAD001 in Combination With PKC412 in Patients With Relapsed, Refractory or Poor Prognosis AML or MDS

Dana-Farber Cancer Institute

Phase 1 Active not recruiting
29 enrolled
MyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡